- Home
- DBD vs BCRX Comparison
DBD vs BCRX Comparison
Compare DBD & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- BCRX
- Stock Information
- Founded
- DBD 1859
- BCRX 1986
- Country
- DBD United States
- BCRX United States
- Employees
- DBD N/A
- BCRX N/A
- Industry
- DBD EDP Services
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DBD Technology
- BCRX Health Care
- Exchange
- DBD Nasdaq
- BCRX Nasdaq
- Market Cap
- DBD 1.8B
- BCRX 1.7B
- IPO Year
- DBD N/A
- BCRX 1994
- Fundamental
- Price
- DBD $40.27
- BCRX $7.03
- Analyst Decision
- DBD Strong Buy
- BCRX Buy
- Analyst Count
- DBD 2
- BCRX 6
- Target Price
- DBD $57.50
- BCRX $14.67
- AVG Volume (30 Days)
- DBD 255.4K
- BCRX 2.5M
- Earning Date
- DBD 11-07-2024
- BCRX 11-04-2024
- Dividend Yield
- DBD N/A
- BCRX N/A
- EPS Growth
- DBD N/A
- BCRX N/A
- EPS
- DBD 0.00
- BCRX N/A
- Revenue
- DBD $3,799,000,000.00
- BCRX $412,579,000.00
- Revenue This Year
- DBD $0.86
- BCRX $37.24
- Revenue Next Year
- DBD $1.19
- BCRX $19.30
- P/E Ratio
- DBD $7,622.28
- BCRX N/A
- Revenue Growth
- DBD 2.88
- BCRX 29.92
- 52 Week Low
- DBD $22.74
- BCRX $4.03
- 52 Week High
- DBD $51.81
- BCRX $8.88
- Technical
- Relative Strength Index (RSI)
- DBD 34.53
- BCRX 40.38
- Support Level
- DBD $38.50
- BCRX $6.85
- Resistance Level
- DBD $42.00
- BCRX $8.25
- Average True Range (ATR)
- DBD 2.10
- BCRX 0.46
- MACD
- DBD -0.94
- BCRX -0.08
- Stochastic Oscillator
- DBD 8.72
- BCRX 11.32
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are banking which offers integrated solutions for financial institutions and retail which offers solutions, software, and services which improve the checkout process for retailers.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.